NX-1207: Completed Phase II enrollment

Nymox closed recruitment in the open-label, U.S. Phase II NX03-0040 trial evaluating single doses of 2.5 and 15 mg intraprostatic NX-1207 in about 150 patients with low-risk, localized prostate cancer...